HCLTech Delivers Another Year of Stellar Growth With Robust Deal Pipeline
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and year ended March 31, 2023.
The company reported full year revenue $12.6 billion, up 9.6% YoY on the back of strong deal pipeline across its portfolio of digital, cloud, engineering and software. INR revenue for the year crossed the Rs 100,000 crore milestone while constant currency revenue was up 13.7%. Profit After Tax for the year came in at Rs 14,851 crores ($1.84 billion), up 10% YoY and at 14.6% of revenue.
During FY23, the company won 57 large deals – 32 in services and 25 in software - that translated into TCV (new deal wins) of $8.85 billion, up 6.6% YoY. Services revenue grew by 15.8% in CC and HCLSoftware Annual Recurring Revenue crossed $1 billion, up 5.2% in CC.
For Q4 FY23, constant currency revenue grew 10.5% YoY while the USD revenue came in at $3.23 billion, up 8.1% YoY. INR revenue was Rs 26,606 crore, up 17.7% YoY. During the quarter, the company won 13 large deals – 10 in services and 3 in software – that translated into a TCV (new deal wins) of $2.07 billion.
HCLTech’s total people count as on March 31, 2023 was 225,944, up 8.2% YoY. Net people addition for FY23 was 17,067, which included the hiring of 26,734 freshers. During Q4 FY23, net people addition was 3,674, which included 4,480 freshers. LTM Attrition during Q4 FY23 further moderated to 19.5%.
“We have delivered a stellar performance in FY'23, crossing ₹ 1,00,000 crores of revenue powered by Industry leading services growth of 15.8% in constant currency. Our net new bookings for FY'23 grew 6.6%. Our pipeline is near an all-time high, which reflects our differentiated business mix and strong client demand for our offerings. We have added 3,674 employees this quarter and overall employee strength has now grown beyond 2,25,000. All these set us well in FY'24 for a healthy revenue growth in the 6-8% range with Operating Margins in 18 -19% range,” said C Vijayakumar, CEO & Managing Director, HCLTech.
“FY'23 concluded with resounding growth of 18.5% in INR and 13.7% in CC, with EBIT at 18.2%. This quarter, we have started publishing a new metric, Annual Recurring Revenue (ARR) for our Software business. It is heartening to note that ARR is at US$ 1Bn+ level, which grew at 5.2% YoY CC (ex. divested business). Profit After Tax (PAT) came in at ₹ 14,851 Cr (14.6%), growing 10% YoY, with EPS at ₹ 54.79. HCLTech Board is pleased to declare ₹ 18/share as the Dividend for the quarter, bringing the total to ₹ 48/share for FY'23, which is 87.5% of the EPS. Cashflow conversion remains robust with OCF / PAT at 121% and FCF / PAT at 110%,” added Prateek Aggarwal, CFO, HCLTech.
HCLTech also demonstrated significant progress in its sustainability agenda:
- MSCI ESG Ratings upgraded HCLTech’s rating to AA from A
- S&P Global Sustainability Yearbook 2023 has recognized HCLTech as an ‘Industry Mover’
- Included in Sustainalytics’ 2023 Top-Rated ESG Companies list in the Software & Services Industry segment & in the Asia Pacific Region
About HCLTech
HCLTech is a global technology company, home to more than 225,900 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG, and Public Services. Consolidated revenues as of 12 months ending March 2023 totaled $12.6 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005229/en/
Contact information
For further details, please contact:
Michelle Rico, Americas
michelle.rico@hcl.com
Elka Ghudial, EMEA
elka.ghudial@hcl.com
James Galvin, ANZ
james.galvin@hcl.com
Devneeta Pahuja, India and APAC
devneeta.p@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release
Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com
The Podium Welcomes the Conquerors of 2023 Taklimakan Rally!2.6.2023 04:33:00 EEST | Press release
Among the 97 autos and 37 motorcycles who have started the Rally in Aksu on May 20, 76 autos and 31 motos have successfully withstood the tough challenges and reached the finish line. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005748/en/ As the 15th edition of Taklimakan Rally, the 2023 Taklimakan Rally lasts for 13 days. The 4258 km total stage contains 1 SSS, 9 stages and 2 rest days. The rally sets foot in the south west of Xinjiang and covers 3 regions of Aksu, Kashgar and Hotan. The multi-terrain stages together with the beautiful scenery has attracted 231 competitors from China and abroad to participate. In the auto category, the final victory goes to Zi Yungang/Wang Zengrong from Shanxi Yunxiang Team. Team BAIC contributes to the podium with Zhang Guoyu/Oriol Mena Valdearcos and Liu Yangui/Chen Feng listed the 2nd and 3rd place. As to the moto, Bradley John Cox and Arunas Gelazninkas continued their good per
UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 19:40:00 EEST | Press release
More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005886/en/ Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom